Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Blood (2023) 142 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2023-188013

Published: 2023

Journal Articles

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Bryon Johnson, PhD, Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140425

Published: 2020

Journal Articles

Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Jordan Milner, Cydney Nichols, Janet Ayello, MS, MT(ASCP), Karen P. Seiter, MD, Delong Liu, MD PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Yaya Chu, PhD, Rosemarie Shaw, Carmella van de Ven, MA, Allyson M. Flower, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-137668

Published: 2020

Journal Articles

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 1990.

https://doi.org/10.1182/blood-2019-126757

Published: 2019

Journal Articles

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Blood (2018) 132 (Supplement 1): 162.

https://doi.org/10.1182/blood-2018-162

Published: 2018

Journal Articles

Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice

Aradhana Awasthi, Janet Ayello, MS, Carmella van de Ven, MA, Asana Love, Mitchell S. Cairo, MD

Blood (2016) 128 (22): 4126.

https://doi.org/10.1182/blood.V128.22.4126.4126

Published: 2016

Journal Articles

A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)

Blood (2016) 128 (22): 4671.

https://doi.org/10.1182/blood.V128.22.4671.4671

Published: 2016

Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 5117.

https://doi.org/10.1182/blood.V126.23.5117.5117

Published: 2015

Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 4852.

https://doi.org/10.1182/blood.V126.23.4852.4852

Published: 2015

Journal Articles

Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL

Sanghoon Lee, PhD MSc, Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 3656.

https://doi.org/10.1182/blood.V126.23.3656.3656

Published: 2015

Journal Articles

Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

Aradhana Tiwari, Delphine CM Rolland, PharmD, PhD, Mona Elmacken, MD, Janet Ayello, MS, Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damine Fermin, PhD, Matthew J. Barth, MD, Christian Klein, PhD, Kojo Elenitoba-Johnson, Megan S Lim, MD PhD, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 1550.

https://doi.org/10.1182/blood.V126.23.1550.1550

Published: 2015

Journal Articles

Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2015) 126 (23): 2732.

https://doi.org/10.1182/blood.V126.23.2732.2732

Published: 2015

Journal Articles

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

Changhong Yin, MS, Sanghoon Lee, PhD MSc., Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 4492.

https://doi.org/10.1182/blood.V124.21.4492.4492

Published: 2014

Journal Articles

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Aradhana Awasthi, PhD, Delphine C.M. Rolland, PharmD, PhD, Mona Elmacken, MD, Christopher Reggio, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damian Fermin, PhD, Matthew J. Barth, MD, Kojo S.J. Elenitoba-Johnson, MD, Megan S Lim, MD PhD, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 5481.

https://doi.org/10.1182/blood.V124.21.5481.5481

Published: 2014

Journal Articles

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Aradhana Awasthi, PhD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mona Elmacken, MD, Christopher Reggio, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2014) 124 (21): 2251.

https://doi.org/10.1182/blood.V124.21.2251.2251

Published: 2014

Journal Articles

Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Timmy O'Connell, MS, Carmella van de Ven, MA, Miguel Muniz, AAS, Matthew J. Barth, MD, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 2503.

https://doi.org/10.1182/blood.V122.21.2503.2503

Published: 2013

Journal Articles

Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Janet Ayello, MS, MT(ASCP), Michael Genualdi, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 4883.

https://doi.org/10.1182/blood.V122.21.4883.4883

Published: 2013

Journal Articles

Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Burkitt Lymphoma (BL) Regression and Improve Survival In Human BL Xenografted NSG Mice

Yaya Chu, PhD, Ashlin Yahr, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Xianzheng Zhou, MD, PhD, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 3263.

https://doi.org/10.1182/blood.V122.21.3263.3263

Published: 2013

Journal Articles

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Changhong Yin, MS, Tae-Hoon Chung, PhD, Janet Ayello, MS, MT(ASCP), Tae-Hyun Park, MS, Carmella van de Ven, MA, Mitchell S. Cairo, MD, Sanghoon Lee, Ph.D, MSc.

Blood (2013) 122 (21): 3852.

https://doi.org/10.1182/blood.V122.21.3852.3852

Published: 2013

Journal Articles

Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL

Sanghoon Lee, PhD, MSc, Changhong Yin, MS, Timmy O'Connell, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2013) 122 (21): 1279.

https://doi.org/10.1182/blood.V122.21.1279.1279

Published: 2013

NARROW

Treatment of Refractory Adenovirus (ADV) Infections Using Adv-Specific Cytotoxic T-Lymphocytes (CTLs) in Children, Adolescents and Young Adults (CAYA) Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), Solid Organ Transplantation (SOT), or with Primary Immunodeficiency (PID)

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD)

Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice

A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL

Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL

Obinutuzumab (GA101) Significantly Inhibits Cell Proliferation and Induces Programmed Cell Death in Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May be a Future Targeted Agent for the Treatment of PMBL

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis

Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model

Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Burkitt Lymphoma (BL) Regression and Improve Survival In Human BL Xenografted NSG Mice

Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL

Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikba In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only